ArticlePloS one2015
Three Dimensional Culture of Human Renal Cell Carcinoma Organoids.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04342286 (To Establish a Reproducible Organoid Culture Model With Human Kidney Cancer), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
To Establish a Reproducible Organoid Culture Model With Human Kidney Cancer
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Establishment of a clear cell renal cell carcinoma organoid cohort integrated into the UroCCR clinical database: A feasibility study.Translational oncology · 2026Article
- Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients.Journal of translational medicine · 2025Review
- In Vivo Performance of a Novel Hyper-Crosslinked Carbohydrate Polymer Bone Graft Substitute for Spinal Fusion.Bioengineering (Basel, Switzerland) · 2025Article
- Organoids in cancer therapies: a comprehensive review.Frontiers in bioengineering and biotechnology · 2025Review
- Organoids as Sophisticated Tools for Renal Cancer Research: Extensive Applications and Promising Prospects.Cellular and molecular bioengineering · 2024Review
- The potential of organoids in renal cell carcinoma research.BMC urology · 2024Review
- The establishment of kidney cancer organoid line in drug testing.Cancer medicine · 2024Article
- Endoplasmic Reticulum Stress in Renal Cell Carcinoma.International journal of molecular sciences · 2023Review
- 3D cancer models: One step closer toFrontiers in immunology · 2023Review
- Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers.BMB reports · 2023Review
- Urological cancer organoids, patients' avatars for precision medicine: past, present and future.Cell & bioscience · 2022Review
- Patient-derived renal cell carcinoma organoids for personalized cancer therapy.Clinical and translational medicine · 2022Article
- The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma Determines Cancer Associated Fibroblast Growth.Cancers · 2021Article
- Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance.Nano convergence · 2021Review
- Genetic engineering in organoids.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Bioengineered Kidney Models: Methods and Functional Assessments.Function (Oxford, England) · 2021Review
- Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma.British journal of cancer · 2020Article
- An organoids biobank for recapitulating tumor heterogeneity and personalized medicine.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- Conditional reprogramming: Modeling urological cancer and translation to clinics.Clinical and translational medicine · 2020Review
- Choosing The Right Animal Model for Renal Cancer Research.Translational oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Renal cell carcinomas arise from the nephron but are heterogeneous in disease biology, clinical behavior, prognosis, and response to systemic therapy. Development of patient-specific in vitro models that efficiently and faithfully reproduce the in vivo phenotype may provide a means to develop personalized therapies for this diverse carcinoma. Studies to maintain and model tumor phenotypes in vitro were conducted with emerging three-dimensional culture techniques and natural scaffolding materials. Human renal cell carcinomas were individually characterized by histology, immunohistochemistry, and quantitative PCR to establish the characteristics of each tumor. Isolated cells were cultured on renal extracellular matrix and compared to a novel polysaccharide scaffold to assess cell-scaffold interactions, development of organoids, and maintenance of gene expression signatures over time in culture. Renal cell carcinomas cultured on renal extracellular matrix repopulated tubules or vessel lumens in renal pyramids and medullary rays, but cells were not observed in glomeruli or outer cortical regions of the scaffold. In the polysaccharide scaffold, renal cell carcinomas formed aggregates that were loosely attached to the scaffold or free-floating within the matrix. Molecular analysis of cell-scaffold constructs including immunohistochemistry and quantitative PCR demonstrated that individual tumor phenotypes could be sustained for up to 21 days in culture on both scaffolds, and in comparison to outcomes in two-dimensional monolayer cultures. The use of three-dimensional scaffolds to engineer a personalized in vitro renal cell carcinoma model provides opportunities to advance understanding of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.